

Special Issue

Tackling Antimicrobial Resistance – From Resistance Monitoring to Antimicrobials Development

Message from the Guest Editors

Nowadays, the emergence and dissemination of antimicrobial-resistant strains constitute a critical global problem in both human and veterinary medicine, being classified as one of the top three priorities in terms of Public Health by the Tripartite Alliance constituted by the Food and Agriculture Organization (FAO), by the World Organization for Animal Health (WOAH) and the World Health Organization (WHO). This phenomenon, sometimes described as the “post-antibiotic era” or “silent pandemic”, is a general concern, not only among health professionals and academia but also among the community. Recently, a series of measures and strategies that should be adopted in order to reduce the frequency of resistant strain development and to contribute to maintaining the effectiveness of available antimicrobials has been identified. This Special Issue aims to publish manuscripts that focus on research aiming at tackling antimicrobial resistance, ranging from resistance monitoring to the development of new antimicrobial alternatives, including new compounds and delivery systems.

Guest Editors

Dr. Eva Cunha

1. Centre for Interdisciplinary Research in Animal Health (CIISA), Faculty of Veterinary Medicine, University of Lisbon, 1300-477 Lisboa, Portugal
2. Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), 1300-477 Lisboa, Portugal

Dr. Manuela Oliveira

1. Centre for Interdisciplinary Research in Animal Health (CIISA), Faculty of Veterinary Medicine, University of Lisbon, 1300-477 Lisboa, Portugal
2. Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), 1300-477 Lisboa, Portugal
3. Centre for Ecology, Evolution and Environmental Changes (cE3c) & Global Change and Sustainability Institute (CHANGE), Faculty of Sciences, University of Lisbon, Campo Grande, 1749-016 Lisboa, Portugal

Deadline for manuscript submissions

closed (1 August 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/161601

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)